Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of August 2024, specifically detailing a capital transaction announced on August 8, 2024, with an expected closing date of August 12, 2024. The Company, a biopharmaceutical firm based in Israel, entered into an inducement offer letter to facilitate the exercise of existing warrants by a specific holder in exchange for the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Expected Gross Proceeds: Approximately $5.0 million from the exercise of existing warrants.
- Existing Warrants Exercised: 2,857,143 ADSs at an exercise price of $1.75 per ADS.
- New Warrants Issued: 5,714,286 ADSs at an exercise price of $2.25 per ADS.
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee on gross proceeds; issuance of warrants for 200,000 ADSs to the agent.
- Other Expenses: Up to $50,000 for non-accountable expenses, $25,000 for accountable expenses, and $15,950 for clearing fees.
- Use of Proceeds: Funding research and development, clinical trials, working capital, and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Transaction Structure
The primary material change is the inducement transaction designed to bring capital into the company. The Company agreed to issue new warrants with a higher exercise price ($2.25) to induce the holder to exercise existing warrants with a lower exercise price ($1.75). The new warrants have varying durations: 5 years for 2,987,012 warrants and 20 months for 2,727,274 warrants. The transaction includes a 90-day lock-up period on issuing new ADSs or filing new registration statements and a one-year restriction on Variable Rate Transactions.
Guidance, Outlook, and Risks
- Outlook: The Company expects to utilize the net proceeds to advance its clinical trials and R&D pipeline.
- Risks and Contingencies: The closing is subject to customary conditions. The filing includes a standard warning that forward-looking statements regarding the closing date and use of proceeds are not guaranteed.
- Liquidity Risks: The new warrants and placement agent warrants will not be listed on any securities exchange, resulting in extremely limited liquidity for these instruments.
- Ownership Limits: Holders are restricted from exercising warrants if it would result in ownership exceeding 4.99% (or 9.99% with notice) of outstanding ordinary shares.
Investor Verification Checklist
- Verify the actual closing of the transaction and the receipt of the $5.0 million gross proceeds.
- Confirm the effective date of the resale registration statement for the new warrant shares (expected within 90 days of August 8, 2024).
- Monitor the Company's cash burn rate and runway extension resulting from this capital raise.
- Review the specific terms of the "Fundamental Transaction" clause in the new warrants regarding potential cash-out options.
- Check for any subsequent filings regarding the 90-day lock-up period expiration and potential new equity issuances.